161 related articles for article (PubMed ID: 37807937)
1. Deferiprone versus deferoxamine for transfusional iron overload in sickle cell disease and other anemias: Pediatric subgroup analysis of the randomized, open-label FIRST study.
Hamdy M; El-Beshlawy A; Veríssimo MPA; Kanter J; Inusa B; Williams S; Lee D; Temin NT; Fradette C; Tricta F; Ebeid FSE; Kwiatkowski JL; Elalfy MS
Pediatr Blood Cancer; 2024 Jan; 71(1):e30711. PubMed ID: 37807937
[TBL] [Abstract][Full Text] [Related]
2. Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study.
Kwiatkowski JL; Hamdy M; El-Beshlawy A; Ebeid FSE; Badr M; Alshehri A; Kanter J; Inusa B; Adly AAM; Williams S; Kilinc Y; Lee D; Tricta F; Elalfy MS
Blood Adv; 2022 Feb; 6(4):1243-1254. PubMed ID: 34847228
[TBL] [Abstract][Full Text] [Related]
3. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
Fortin PM; Fisher SA; Madgwick KV; Trivella M; Hopewell S; Doree C; Estcourt LJ
Cochrane Database Syst Rev; 2018 May; 5(5):CD012349. PubMed ID: 29737522
[TBL] [Abstract][Full Text] [Related]
4. Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years.
Elalfy MS; Hamdy M; El-Beshlawy A; Ebeid FSE; Badr M; Kanter J; Inusa B; Adly AAM; Williams S; Kilinc Y; Lee D; Fradette C; Rozova A; Temin NT; Tricta F; Kwiatkowski JL
Blood Adv; 2023 Feb; 7(4):611-619. PubMed ID: 36018224
[TBL] [Abstract][Full Text] [Related]
5. Oral deferiprone for iron chelation in people with thalassaemia.
Fisher SA; Brunskill SJ; Doree C; Chowdhury O; Gooding S; Roberts DJ
Cochrane Database Syst Rev; 2013 Aug; (8):CD004839. PubMed ID: 23966105
[TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetic and safety profile of single-dose deferiprone in subjects with sickle cell disease.
Soulières D; Mercier-Ross J; Fradette C; Rozova A; Tsang YC; Tricta F
Ann Hematol; 2022 Mar; 101(3):533-539. PubMed ID: 34981144
[TBL] [Abstract][Full Text] [Related]
7. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
Fisher SA; Brunskill SJ; Doree C; Gooding S; Chowdhury O; Roberts DJ
Cochrane Database Syst Rev; 2013 Aug; (8):CD004450. PubMed ID: 23963793
[TBL] [Abstract][Full Text] [Related]
8. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
Maggio A; Kattamis A; Felisi M; Reggiardo G; El-Beshlawy A; Bejaoui M; Sherief L; Christou S; Cosmi C; Della Pasqua O; Del Vecchio GC; Filosa A; Cuccia L; Hassab H; Kreka M; Origa R; Putti MC; Spino M; Telfer P; Tempesta B; Vitrano A; Tsang YC; Zaka A; Tricta F; Bonifazi D; Ceci A
Lancet Haematol; 2020 Jun; 7(6):e469-e478. PubMed ID: 32470438
[TBL] [Abstract][Full Text] [Related]
10. Deferiprone versus deferoxamine in sickle cell disease: results from a 5-year long-term Italian multi-center randomized clinical trial.
Calvaruso G; Vitrano A; Di Maggio R; Ballas S; Steinberg MH; Rigano P; Sacco M; Telfer P; Renda D; Barone R; Maggio A;
Blood Cells Mol Dis; 2014 Dec; 53(4):265-71. PubMed ID: 24814618
[TBL] [Abstract][Full Text] [Related]
11. The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload.
ElAlfy MS; Sari TT; Lee CL; Tricta F; El-Beshlawy A
J Pediatr Hematol Oncol; 2010 Nov; 32(8):601-5. PubMed ID: 20921906
[TBL] [Abstract][Full Text] [Related]
12. Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial.
Calvaruso G; Vitrano A; Di Maggio R; Lai E; Colletta G; Quota A; Gerardi C; Rigoli LC; Sacco M; Pitrolo L; Maggio A
Am J Hematol; 2015 Jul; 90(7):634-8. PubMed ID: 25809173
[TBL] [Abstract][Full Text] [Related]
13. Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand.
Viprakasit V; Nuchprayoon I; Chuansumrit A; Torcharus K; Pongtanakul B; Laothamatas J; Srichairatanakool S; Pooliam J; Supajitkasem S; Suriyaphol P; Tanphaichitr VS; Tuchinda S
Am J Hematol; 2013 Apr; 88(4):251-60. PubMed ID: 23460233
[TBL] [Abstract][Full Text] [Related]
14. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.
Neufeld EJ
Blood; 2006 May; 107(9):3436-41. PubMed ID: 16627763
[TBL] [Abstract][Full Text] [Related]
15. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
16. Deferasirox for managing transfusional iron overload in people with sickle cell disease.
Meerpohl JJ; Antes G; Rücker G; Fleeman N; Niemeyer C; Bassler D
Cochrane Database Syst Rev; 2010 Aug; (8):CD007477. PubMed ID: 20687088
[TBL] [Abstract][Full Text] [Related]
17. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.
Taher A; Sheikh-Taha M; Koussa S; Inati A; Neeman R; Mourad F
Eur J Haematol; 2001 Jul; 67(1):30-4. PubMed ID: 11553264
[TBL] [Abstract][Full Text] [Related]
18. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.
Marsella M; Borgna-Pignatti C
Hematol Oncol Clin North Am; 2014 Aug; 28(4):703-27, vi. PubMed ID: 25064709
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of deferiprone as twice-a-day tablets or in combination therapy for the treatment of transfusional iron overload in thalassemia syndromes.
Shah R; Shah A; Badawy SM
Expert Rev Hematol; 2023 Feb; 16(2):81-94. PubMed ID: 36755516
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of deferoxamine, deferasirox and deferiprone triple iron chelator combination therapy for transfusion-dependent β-thalassaemia with very high iron overload: a protocol for randomised controlled clinical trial.
Premawardhena A; Perera C; Wijethilaka MN; Wanasinghe SK; Rajakaruna RHMG; Samarasinghe RANKK; Williams S; Mettananda S
BMJ Open; 2024 Feb; 14(2):e077342. PubMed ID: 38331857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]